Funding Opportunity PAR-25-081 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.

Funding Opportunity PAR-25-167 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.

£39,950 - £45,275 with benefits, subject to skills and experience : The Francis Crick Institute: We are a multi-disciplinary research group with a mission to understand the factors underlying an organ’s regenerative capacity. London (Central), London (Greater)

Funding Opportunity PAR-25-133 from the NIH Guide for Grants and Contracts. This announcement encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: University of Nottingham: Applications are invited for a Research Associate/Fellow to work on a Medical Research Council funded project using multiple molecular genetics techni University Park, United Kingdom

Competitive: Origin Sciences: Origin Sciences is a start-up biotechnology company based in Granta Park, just south of Cambridge. We develop our own innovative medical devices, whic Cambridge, United Kingdom

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: T Cypher Bio: Senior Bioinformatician - In-silico protein design T-Cypher Bio is an early-stage, innovative biotechnology company aiming to unlock an expansive ta Oxford, Oxfordshire, United Kingdom

Competitive: University of Leicester Recruitment Team: The Leicester van Geest Multi-Omics Research Group is seeking a highly skilled Laboratory Technician with extensive experience in performing proteomic Leicester, Leicestershire, United Kingdom

Competitive: University of Nottingham: Applications are invited for two Assistant Professor of Microbiology positions within the School of Life Sciences (SoLS), University of Nottingham. UK Other, United Kingdom

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: HCA Healthcare: Clinical Analyst - Acute Care 1 London Bridge Full-Time 37.5 per week Permanent HCA Healthcare UK's Information Technology Group (ITG) is a Group London, United Kingdom

Funding Opportunity PAR-25-027 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentists from NIH Intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution.

Funding Opportunity PAR-25-108 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. The R21 FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy, imaging, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy.

Notice NOT-HL-24-029 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-201 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites implementation research applications to develop, optimize, and test innovative theory-based strategies to integrate mental health care into health care systems - integrating mental and physical health care - and other community settings - schools, community center and others- within health care systems in low-and middle-income countries (LMICs). This NOFO aims to support innovative research for implementing, scaling up, and financially sustaining integrated mental health care models to ultimately increase demand and utilization, quality, access, and availability of mental health care. This NOFO is also expected to contribute to the long-term goals of strengthening the sustainable research capacity in LMICs and enhancing the potential for multidirectional knowledge and the exchange of research advancements. NIMH encourages partnerships between institutions in LMICs and high-income-countries (HICs).

Funding Opportunity PAR-25-237 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings.

Notice NOT-MH-25-060 from the NIH Guide for Grants and Contracts